Axsome Therapeutics Inc. focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. The company was founded in 2012 and is based in New York City, New York.
Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat. A live webcast and archive of the William Blair event can be viewed on the "Webcasts & Presentations" page of the "Investors" section of the Company's website at www.axsome.com. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options.
Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that data from the GEMINI Phase 3 trial of AXS-05 in major depressive disorder (MDD) will be presented in oral and poster sessions at the 2020 Annual Meeting of the American Society for Clinical Psychopharmacology (ASCP), to be held virtually, May 29-30. AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.
Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the Company’s 2020 Annual Meeting of Stockholders will now be held in a virtual-only meeting format due to continued public health concerns resulting from the COVID-19 pandemic, government-recommended and required limits on public gatherings, and to protect the health and safety of the Company’s stockholders, directors, and employees. Stockholders will not be able to attend the Annual Meeting in person. The Company’s stockholders as of the close of business on April 9, 2020 (the “Record Date”) can join the live virtual meeting.